stoichiometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
The sequence carries three residues in the order glycine, histidine, lysine, which places a small, flexible chain around a single metal centre. Compared with larger copper-binding proteins, the complex is compact and its coordination chemistry can be reproduced with synthetic peptide in a laboratory. Published structural work agrees on the nitrogen donor set but differs in the exact geometry assigned under some conditions, so the arrangement is best treated as well characterised in outline rather than fixed in every detail.
| Property | Value | Notes |
|---|---|---|
| Long-term storage | -20 °C | Dry powder, sealed and protected from light |
| Working storage | 2 to 8 °C | Short-term holding; avoid repeated warming cycles |
| Purity assay | Reversed-phase HPLC with UV detection | Detection commonly near 214 nm |
| Copper assay | ICP-OES or atomic absorption | Confirms metal content and the metal-to-peptide ratio |
| Visible absorption | Roughly 520 to 600 nm | Rapid indicator of complex integrity |
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
The plasma is strongly collisional, so that the collision time scale is shorter than the other characteristic time scales in the system, and the particle distributions are therefore close to Maxwellian. The resistivity due to these collisions is small. In particular, the typical magnetic diffusion time over any length scale present in the system must be longer than any time scale of interest. The relevant length scales are much longer than the ion skin depth and the Larmor radius perpendicular to the field, sufficiently long scales along the field to ignore Landau damping, and time scales much longer than the ion gyration time (that is, the system is smooth and slowly evolving).
== Chemical Protein Synthesis == Native chemical ligation of unprotected peptide segments is used to prepare the protein's polypeptide chain, which is then folded to form a protein molecule. In native chemical ligation, a peptide C-terminal thioester reacts with a second peptide that has a cysteine residue at its N-terminus, to give a product with a peptide bond at the ligation site. Multiple unprotected peptide segments can be linked in this way to give the full length polypeptide chain, which is folded to give the target protein molecule. Once the chemical synthesis of an L-protein is achieved, the D-protein enantiomer can be prepared using synthetic peptide building blocks made from D-amino acids and Gly. Convergent synthesis is most effective in preparing long polypeptide chains using synthetic peptide-hydrazides, where the hydrazide can be converted to a thioester for use in native chemical ligation. The hydrazide is stable to native chemical ligation reaction conditions, and can be converted in situ to a reactive peptide-thioester for the next native chemical ligation condensation reaction.
==== Distribution of inefficient medicine and harms to health ==== One of the first acts under Melo's administration was to buy, among other medicines, azithromycin, ivermectin, and hydroxychloroquine and chloroquine – the latter of two which had been approved for the treatment of malaria – to supposedly combat COVID-19, despite multiple studies showing that all the medicines bought were ineffective towards treating the virus. The controversial decision was brought to suit by PSOL, which alleged that his administration was using public money to buy the medicine. The measure was also criticized by the council of the Faculty of Medicine at the Federal University of Rio Grande do Sul that asked for the immediate suspension of their distribution. Melo justified the purchase with the Ministry of Medicine by stating that people in the middle and upper-middle classes, and their friends, were taking the medicine. In total, the city government bought 239,000 reais worth of the medications, which they packaged into what they called the "COVID kit". Along with their ineffectiveness, it has been reported that the use of the medications combined over a long period and in high doses could lead to liver and renal damage, leading to the need for a liver transplant or possibly death. In February, the Justice ministry prohibited, in a liminary decision, the city from distributing the kit. In the decision, the judge argued that the prohibition would be necessary while robust evidence, based on clinical studies and recognized by the scientific community, did not exist.
The first state to switch to this method was Ohio, on December 8, 2009. In 2011, after pressure from activist organizations, the manufacturers of pentobarbital and sodium thiopental halted the supply of the drugs to U.S. prisons performing lethal injections and required all resellers to do the same.
Sources: en.wikipedia.org
MAL-LAD, or MALLAD, also known as METAL-LAD or METALLAD, as well as 6-methallyl-6-nor-LSD, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD). The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor among others. It is also a dopamine receptor agonist, though unlike other lysergamides, does not show activity at the dopamine D1 and D5 receptors. MAL-LAD does not appear to have been assessed in animal tests of psychedelic-like activity such as drug discrimination. MAL-LAD was first described in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University by 1987. It was subsequently further described by a group of researchers that included Nichols and other colleagues in 2025. The drug is not a controlled substance in Canada as of 2025.
Neal Benowitz, a professor of medicine at UC San Francisco who is an expert on ephedrine and other stimulants, agreed that "These [levels] are what you'd see from someone taking cold or allergy medicines and are unlikely to have any effect on performance." Following Exum's revelations the IAAF acknowledged that at the 1988 Olympic Trials the USOC indeed followed the correct procedures in dealing with eight positive findings for ephedrine and ephedrine-related compounds in low concentration. The federation also reviewed in 1988 the relevant documents with the athletes' names undisclosed and stated that "the medical committee felt satisfied, however, on the basis of the information received that the cases had been properly concluded by the USOC as 'negative cases' in accordance with the rules and regulations in place at the time and no further action was taken".
Because β-alanine dipeptides are not incorporated into proteins, they can be stored at relatively high concentrations. Occurring at 17–25 mmol/kg (dry muscle), carnosine (β-alanyl-L-histidine) is an important intramuscular buffer, constituting 10-20% of the total buffering capacity in type I and II muscle fibres. In carnosine, the pKa of the imidazolium group is 6.83, which is ideal for buffering.
=== Thermal properties === Solid silver nitrate is robust and melts to give a dense (4.1 g/cm3), stable liquid above its 198 °C melting point. At temperatures around 250 °C it decomposes to release metallic silver and red-brown fumes of nitrogen dioxide. Full decomposition occurs at 440 °C.
Most specimens are of little value for research without accompanying information, such as the time and place the bird was found or collected. This and other important information, such as mass, sex, fat deposition, and degree of skull ossification, is written on a label along with a unique field and museum number. Modern computerized museum databases include all of this information for each specimen, as well as the types of methods used to prepare the bird. Modern collections seek to maximize the utility of each preserved individual, and this includes recording detailed information about it. Most modern specimens also include a tissue sample preserved for genetic study. Online access to collections' data is becoming increasingly available, and a cross-institutional database covering millions of computerized bird records is in development. Freeze drying of whole specimens, especially of small birds, has been adopted for use in teaching collections.
Sources: en.wikipedia.org
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.
The colour comes from electronic transitions between the copper ion and the surrounding peptide nitrogen atoms. The resulting absorption sits in the visible region, giving the solid and its solutions a blue to violet appearance. Loss of colour can indicate that the copper has dissociated from the peptide.
Chromatography establishes the identity and purity of the peptide, while elemental analysis establishes the copper content. The two results should agree with a one-to-one ratio. Visible spectroscopy adds a quick check that the complex itself is intact.
It consists of a three-amino-acid peptide, glycine-histidine-lysine, bound to one copper(II) ion. The peptide supplies four nitrogen donor atoms, and the resulting complex is stable in neutral aqueous solution. The metal-free peptide is usually called GHK.